What is Leerink Partnrs’ Estimate for Exelixis Q1 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Leerink Partnrs boosted their Q1 2025 earnings per share estimates for Exelixis in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings per share of $0.36 for the quarter, up from their prior estimate of $0.35. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Leerink Partnrs also issued estimates for Exelixis’ Q2 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.68 EPS and FY2025 earnings at $2.15 EPS.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

A number of other brokerages have also commented on EXEL. Bank of America lowered Exelixis from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. BMO Capital Markets downgraded Exelixis from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $36.00 to $40.00 in a report on Friday, December 20th. Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Citigroup upped their target price on shares of Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Finally, Brookline Capital Management assumed coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.59.

Exelixis Price Performance

NASDAQ:EXEL opened at $36.84 on Friday. Exelixis has a one year low of $20.14 and a one year high of $40.02. The company has a market cap of $10.31 billion, a PE ratio of 20.81, a PEG ratio of 1.13 and a beta of 0.57. The firm has a 50-day moving average of $35.70 and a 200-day moving average of $33.14.

Hedge Funds Weigh In On Exelixis

Several hedge funds have recently made changes to their positions in EXEL. Natixis Advisors LLC boosted its stake in Exelixis by 26.2% in the 3rd quarter. Natixis Advisors LLC now owns 29,113 shares of the biotechnology company’s stock worth $755,000 after purchasing an additional 6,051 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of Exelixis by 3.2% in the third quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock worth $515,000 after buying an additional 609 shares in the last quarter. Cerity Partners LLC boosted its position in shares of Exelixis by 129.1% in the third quarter. Cerity Partners LLC now owns 27,994 shares of the biotechnology company’s stock valued at $726,000 after acquiring an additional 15,777 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Exelixis during the third quarter valued at approximately $591,000. Finally, Bank of Montreal Can increased its holdings in Exelixis by 51.5% during the 3rd quarter. Bank of Montreal Can now owns 104,385 shares of the biotechnology company’s stock worth $2,710,000 after acquiring an additional 35,496 shares during the period. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the transaction, the executive vice president now owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jack L. Wyszomierski sold 8,768 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the sale, the director now owns 356,605 shares in the company, valued at $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 over the last ninety days. 2.85% of the stock is currently owned by insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.